David Pinsky
15Patents
7h-index
20Co-inventors
66Inventor score
Filing activity: Oct 4, 1993 → Nov 24, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5552267A | Solution for prolonged organ preservation | Human Necessities | 111 | Expired |
| US5370989A | Solution for prolonged organ preservation | Human Necessities | 80 | Expired |
| US6315995A | Methods for treating an ischemic disorder and improving stroke outcome | Chemistry; Metallurgy | 55 | Expired |
| US6316403A | Methods for treating an ischemic disorder and improving stroke outcome | Chemistry; Metallurgy | 54 | Expired |
| US6969704B1 | Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject | Chemistry; Metallurgy | 31 | Expired |
| US5728705A | Method of inducing vasorelaxation to treat pulmonary hypertension | Human Necessities | 13 | Expired |
| US5968911A | Method of inducing vasorelaxation to treat pulmonary hypertension | Human Necessities | 11 | Expired |
| US8128963B2 | Methods for treating ischemic disorders using carbon monoxide | Chemistry; Metallurgy | 5 | Active |
| US10342821B2 | Systems and methods to improve organ or tissue function and organ or tissue transplant longevity | Physics | 2 | Active |
| US6867177B2 | CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders | Human Necessities | 2 | Expired |
| US9789133B2 | Systems and methods to improve organ or tissue function and organ or tissue transplant longevity | Physics | 2 | Active |
| US6972175B2 | Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods | Physics | 1 | Expired |
| US11389471B2 | Systems and methods to improve organ or tissue function and organ or tissue transplant longevity | Physics | 0 | Active |
| US10874719B2 | Nucleotide phosphate dissipation as a treatment for vascular disorders | Chemistry; Metallurgy | 0 | Active |
| US12029755B2 | Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.